First‐in‐Human Single and Multiple Ascending Dose Studies of Balinatunfib, a Small Molecule Inhibitor of TNFR1 Signaling in Healthy Participants
Authors:
- Nassr NassrNNNassr Nassr
- Faiza RharbaouiFRFaiza Rharbaoui
- Dietmar WeitzDWDietmar Weitz
- Johann GassenhuberJGJohann Gassenhuber
- Markus RehbergMRMarkus Rehberg
- Markus KohlmannMKMarkus Kohlmann
- Fabienne SchumacherFSFabienne Schumacher
- Amel LahmarALAmel Lahmar
- Andreas KovarAKAndreas Kovar
- Laurent PerrinLPLaurent Perrin
- Frank‐Dietrich WagnerFWFrank‐Dietrich Wagner
- Maria WiekowskiMWMaria Wiekowski
Open Access
- 30 March 2025
- journal article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 118 (1) , 164-176
Abstract
Oral small molecule inhibitors of tumor necrosis factor alpha (TNFα) are emerging as attractive therapeutic agents for the treatment of various autoimmune diseases. Balinatunfib (SAR441566), a novel oral inhibitor of tumor necrosis factor receptor 1 (TNFR1) signaling, changes the configuration of the soluble TNFα (sTNFα) trimer and prevents its heterotrimerization with TNFR1 but not TNFR2, thereby blocking TNFR1 signaling. Herein, we report the results from a first‐in‐human (FIH) study that evaluated the safety, pharmacokinetics (PK), and pharmacodynamics (PD) following single ascending doses (SAD) and multiple ascending doses (MAD) of balinatunfib in healthy male participants. Single (5–600 mg) and multiple (100–600 mg total daily dose for up to 14 days) oral doses of balinatunfib were well‐tolerated in all participants. Consistent PK data were obtained across the studies, with a median tmax of 2.5–5 hours, a mean terminal half‐life of 22–30 hours, and a time to steady state of 5–6 days. A supra‐proportional exposure increase was observed in both SAD and MAD studies, which was less pronounced at doses ≥ 180 mg. Food had no relevant effects on the PK characteristics of balinatunfib. As the main PD read‐out, complete TNFα occupancy was shown at all tested time points after the treatment started. Balinatunfib, as the first clinically tested oral TNFR1 signal inhibitor, demonstrated a good safety profile along with favorable PK/PD characteristics that allowed both once and twice daily dosing, confirming a successful preclinical‐to‐clinical translation and guiding dose selection for further clinical efficacy studies.Keywords
Funding Information
- Sanofi
This publication has 34 references indexed in Scilit:
- Small-molecule modulators of tumor necrosis factor signalingDrug Discovery Today, 2023
- TNF-α: The shape of small molecules to come?Drug Discovery Today, 2022
- Selective inhibition of Tumor necrosis factor receptor-1 (TNFR1) for the treatment of autoimmune diseasesCytokine & Growth Factor Reviews, 2020
- Psoriatic disease treatment nowadays: unmet needs among the “jungle of biologic drugs and small molecules”Clinical Rheumatology, 2018
- TNFR1 and TNFR2 differentially mediate TNF‐α‐induced inflammatory responses in rheumatoid arthritis fibroblast‐like synoviocytesCell Biology International, 2017
- TNF biology, pathogenic mechanisms and emerging therapeutic strategiesNature Reviews Rheumatology, 2015
- Tumor necrosis factor inhibitors: clinical utility in autoimmune diseasesTranslational Research, 2015
- Patient Preference for Oral Versus Injectable and Intravenous Methods of Treatment for Rheumatoid ArthritisValue in Health, 2013
- Theoretical analysis of efficacy of biological agent for rheumatoid arthritis based on target molecular binding occupancyRheumatology International, 2013
- Levels of circulating tumor necrosis factor α and interleukin‐6 in patients with rheumatoid arthritis. relationship to serum levels of hyaluronan and antigenic keratan sulfateArthritis & Rheumatism, 1993